Short Interest in Ernexa Therapeutics Inc. (NASDAQ:ERNA) Expands By 74.1%

Ernexa Therapeutics Inc. (NASDAQ:ERNA) saw a significant increase in short interest in the month of March. As of March 31st, there was short interest totaling 160,378 shares, an increase of 74.1% from the March 15th total of 92,109 shares. Approximately 0.6% of the company’s shares are sold short. Based on an average trading volume of 1,095,252 shares, the days-to-cover ratio is currently 0.1 days.

Ernexa Therapeutics Stock Up 1.0%

ERNA traded up $0.00 during trading on Monday, hitting $0.20. The company’s stock had a trading volume of 229,996 shares, compared to its average volume of 1,547,815. Ernexa Therapeutics has a twelve month low of $0.18 and a twelve month high of $4.02. The stock’s fifty day moving average price is $0.33 and its 200-day moving average price is $0.97. The firm has a market capitalization of $5.74 million, a P/E ratio of -0.07 and a beta of 6.79.

Ernexa Therapeutics (NASDAQ:ERNA) last issued its quarterly earnings results on Friday, March 13th. The company reported ($0.01) earnings per share (EPS) for the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ernexa Therapeutics in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Ernexa Therapeutics

An institutional investor recently bought a new position in Ernexa Therapeutics stock. Susquehanna International Group LLP bought a new position in shares of Ernexa Therapeutics Inc. (NASDAQ:ERNA) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned 0.39% of Ernexa Therapeutics as of its most recent SEC filing. 70.55% of the stock is currently owned by hedge funds and other institutional investors.

Ernexa Therapeutics Company Profile

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.